search
Back to results

Effects of Novel Fiber on Glucose Metabolism and Insulin Sensitivity

Primary Purpose

Insulin Resistance

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Novel dietary fiber
Novel dietary fiber
Placebo
Sponsored by
Cargill
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Insulin Resistance focused on measuring dietary fiber, fiber, insulin sensitivity, insulin resistance, glucose metabolism

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Male or female of any racial/ethnic group; able to read, comprehend, and write English at a sufficient level to complete study-related materials
  • Age: at least 30 and no more than 70 years at randomization into this trial
  • BMI: 25-40 kg/m2 at randomization into this trial
  • Fasting blood glucose: 95-140 mg/dl (for those with glucose 95-99mg/dl, must have history of gestational diabetes or first degree relative (parent or sibling) with history of diabetes; for those with glucose 100-125 mg/dl, will be enrolled as the primary target for recruitment; for those with glucose 126-140 mg/dl (asymptomatic diabetes), must not have prior diagnosis of diabetes and must not have prior treatment/pharmacotherapy for diabetes)
  • Good general health as evidenced by the medical history
  • Blood chemistry and urinalysis results within normal ranges or within an acceptable range determined by the physician on site and/or in consultation with the Medical Monitor
  • Available and willing to participate in the study for up to 15 weeks
  • Willing to follow a weight-maintaining Lifestyle diet throughout the 12 week trial, maintain physical activity patterns at baseline levels throughout the study period, and not add new exercise routines, dietary supplements, vitamins or other unusual food products
  • Willing to consume two 16 oz beverages every day with meals for 12 weeks and able to transport the test article

Exclusion Criteria:

  • Presence of any condition the Investigator believes would interfere with subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk
  • Food allergy or sensitivity to any of the ingredients in the study product (e.g. Gluten sensitivity, celiac disease)
  • Participation in another clinical trial that might interfere with this trial or exposure to any investigational agent within 30 days prior to first visit
  • History of diabetes (subjects with a prior history of gestational diabetes may be enrolled if they had no pharmacologic treatment for diabetes since pregnancy)
  • Treatment for diabetes or a related condition (e.g., polycystic ovary syndrome) with metformin, an oral agent, or insulin or other injections used for diabetes management
  • Uncontrolled hypertension (i.e., systolic blood pressure >160 mm Hg, or a diastolic blood pressure >95 mmHg based on an average of 3 readings sitting)
  • Fasting serum triglyceride value >250 mg/dl (since changes in triglyceride values can affect glucose homeostasis)
  • Untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit
  • Recent history of weight loss (>4 kg in the past 3 months) or a significant variation in weight (>4 kg in the past 3 months, for example, due to a medical condition such as pregnancy, or hormonal therapy)
  • Use of medications or herbal remedies for weight loss (e.g., sibutramine, orlistat, amphetamines, phentermine, and ma huang) or use of these substances within the past 3 months
  • Current or recent history (past 12 months) of drug, alcohol or chemical abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor)
  • Pregnant, breast-feeding or female of child-bearing potential who is unwilling to commit to the use of a medically approved form of contraception throughout the study period.

Sites / Locations

  • Louisville Metabolic and Atherosclerosis Research Center
  • KGK Synergize Inc.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

Placebo beverage

Arm Description

3g/day

6g/day

0g/day

Outcomes

Primary Outcome Measures

Mean changes in fasting and post-glucose administration values for plasma glucose from baseline to end of study
Mean changes in fasting and post-glucose administration values for plasma insulin from baseline to end of study
Mean changes in blood HbA1c values from baseline to end of study

Secondary Outcome Measures

Mean changes from baseline to end of study in HOMA
Percentage change and absolute change from baseline in body weight
Mean changes from baseline in waist circumference
Mean changes in total body fat, lean tissue and abdominal fat as determined by DEXA [distribution or absolute changes]

Full Information

First Posted
June 16, 2011
Last Updated
June 16, 2011
Sponsor
Cargill
search

1. Study Identification

Unique Protocol Identification Number
NCT01375803
Brief Title
Effects of Novel Fiber on Glucose Metabolism and Insulin Sensitivity
Official Title
Novel Fiber Effects on Glucose Metabolism and Insulin Sensitivity for Individuals at High Risk for Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
June 2011
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
August 2010 (Actual)
Study Completion Date
August 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Cargill

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will critically evaluate the effects of a novel dietary fiber administered to subjects at high risk for developing diabetes to determine if this intervention will improve insulin sensitivity compared to control product administration and, thus, decrease risk for developing diabetes. The hypothesis is that consuming this novel fiber twice a day for 12 weeks will significantly decrease fasting plasma glucose, insulin and glycosylated hemoglobin values in pre-diabetic subjects (i.e. subjects with fasting plasma glucose levels 95-140 mg/dl at screening) compared to consumption of the control product.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Resistance
Keywords
dietary fiber, fiber, insulin sensitivity, insulin resistance, glucose metabolism

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
3g/day
Arm Title
2
Arm Type
Experimental
Arm Description
6g/day
Arm Title
Placebo beverage
Arm Type
Placebo Comparator
Arm Description
0g/day
Intervention Type
Dietary Supplement
Intervention Name(s)
Novel dietary fiber
Intervention Description
oral consumption in beverage
Intervention Type
Dietary Supplement
Intervention Name(s)
Novel dietary fiber
Intervention Description
Oral consumption in beverage
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Oral consumption in beverage
Primary Outcome Measure Information:
Title
Mean changes in fasting and post-glucose administration values for plasma glucose from baseline to end of study
Time Frame
0, 6, 9, 12 weeks
Title
Mean changes in fasting and post-glucose administration values for plasma insulin from baseline to end of study
Time Frame
0, 6, 9, 12 weeks
Title
Mean changes in blood HbA1c values from baseline to end of study
Time Frame
0, 12 weeks
Secondary Outcome Measure Information:
Title
Mean changes from baseline to end of study in HOMA
Time Frame
0, 6, 9, 12 weeks
Title
Percentage change and absolute change from baseline in body weight
Time Frame
0, 3, 6, 9, 12 weeks
Title
Mean changes from baseline in waist circumference
Time Frame
0, 12 weeks
Title
Mean changes in total body fat, lean tissue and abdominal fat as determined by DEXA [distribution or absolute changes]
Time Frame
0, 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female of any racial/ethnic group; able to read, comprehend, and write English at a sufficient level to complete study-related materials Age: at least 30 and no more than 70 years at randomization into this trial BMI: 25-40 kg/m2 at randomization into this trial Fasting blood glucose: 95-140 mg/dl (for those with glucose 95-99mg/dl, must have history of gestational diabetes or first degree relative (parent or sibling) with history of diabetes; for those with glucose 100-125 mg/dl, will be enrolled as the primary target for recruitment; for those with glucose 126-140 mg/dl (asymptomatic diabetes), must not have prior diagnosis of diabetes and must not have prior treatment/pharmacotherapy for diabetes) Good general health as evidenced by the medical history Blood chemistry and urinalysis results within normal ranges or within an acceptable range determined by the physician on site and/or in consultation with the Medical Monitor Available and willing to participate in the study for up to 15 weeks Willing to follow a weight-maintaining Lifestyle diet throughout the 12 week trial, maintain physical activity patterns at baseline levels throughout the study period, and not add new exercise routines, dietary supplements, vitamins or other unusual food products Willing to consume two 16 oz beverages every day with meals for 12 weeks and able to transport the test article Exclusion Criteria: Presence of any condition the Investigator believes would interfere with subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk Food allergy or sensitivity to any of the ingredients in the study product (e.g. Gluten sensitivity, celiac disease) Participation in another clinical trial that might interfere with this trial or exposure to any investigational agent within 30 days prior to first visit History of diabetes (subjects with a prior history of gestational diabetes may be enrolled if they had no pharmacologic treatment for diabetes since pregnancy) Treatment for diabetes or a related condition (e.g., polycystic ovary syndrome) with metformin, an oral agent, or insulin or other injections used for diabetes management Uncontrolled hypertension (i.e., systolic blood pressure >160 mm Hg, or a diastolic blood pressure >95 mmHg based on an average of 3 readings sitting) Fasting serum triglyceride value >250 mg/dl (since changes in triglyceride values can affect glucose homeostasis) Untreated hypothyroidism with a TSH > 1.5 times the upper limit of normal for the test laboratory with repeat value that also exceeds this limit Recent history of weight loss (>4 kg in the past 3 months) or a significant variation in weight (>4 kg in the past 3 months, for example, due to a medical condition such as pregnancy, or hormonal therapy) Use of medications or herbal remedies for weight loss (e.g., sibutramine, orlistat, amphetamines, phentermine, and ma huang) or use of these substances within the past 3 months Current or recent history (past 12 months) of drug, alcohol or chemical abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor) Pregnant, breast-feeding or female of child-bearing potential who is unwilling to commit to the use of a medically approved form of contraception throughout the study period.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Harold E Bays, MD, FACP
Organizational Affiliation
Louisville Metabolic and Atherosclerosis Research Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dale R Wilson, MD, CCFP(EM), FCFP
Organizational Affiliation
KGK Science Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Louisville Metabolic and Atherosclerosis Research Center
City
Louisvile
State/Province
Kentucky
ZIP/Postal Code
40213
Country
United States
Facility Name
KGK Synergize Inc.
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5R8
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
16567814
Citation
Weickert MO, Mohlig M, Schofl C, Arafat AM, Otto B, Viehoff H, Koebnick C, Kohl A, Spranger J, Pfeiffer AF. Cereal fiber improves whole-body insulin sensitivity in overweight and obese women. Diabetes Care. 2006 Apr;29(4):775-80. doi: 10.2337/diacare.29.04.06.dc05-2374.
Results Reference
background
PubMed Identifier
10799374
Citation
Lu ZX, Walker KZ, Muir JG, Mascara T, O'Dea K. Arabinoxylan fiber, a byproduct of wheat flour processing, reduces the postprandial glucose response in normoglycemic subjects. Am J Clin Nutr. 2000 May;71(5):1123-8. doi: 10.1093/ajcn/71.5.1123.
Results Reference
background
PubMed Identifier
14559925
Citation
Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003 Oct;22(5):331-9. doi: 10.1080/07315724.2003.10719316.
Results Reference
background
PubMed Identifier
15930484
Citation
Behall KM, Scholfield DJ, Hallfrisch J. Comparison of hormone and glucose responses of overweight women to barley and oats. J Am Coll Nutr. 2005 Jun;24(3):182-8. doi: 10.1080/07315724.2005.10719464.
Results Reference
background
PubMed Identifier
12080401
Citation
Jenkins AL, Jenkins DJ, Zdravkovic U, Wursch P, Vuksan V. Depression of the glycemic index by high levels of beta-glucan fiber in two functional foods tested in type 2 diabetes. Eur J Clin Nutr. 2002 Jul;56(7):622-8. doi: 10.1038/sj.ejcn.1601367.
Results Reference
background
PubMed Identifier
17445284
Citation
Keenan JM, Goulson M, Shamliyan T, Knutson N, Kolberg L, Curry L. The effects of concentrated barley beta-glucan on blood lipids in a population of hypercholesterolaemic men and women. Br J Nutr. 2007 Jun;97(6):1162-8. doi: 10.1017/S0007114507682968. Epub 2007 Apr 20. Erratum In: Br J Nutr. 2007 Aug;98(2):445.
Results Reference
background
PubMed Identifier
21846371
Citation
Bays H, Frestedt JL, Bell M, Williams C, Kolberg L, Schmelzer W, Anderson JW. Reduced viscosity Barley beta-Glucan versus placebo: a randomized controlled trial of the effects on insulin sensitivity for individuals at risk for diabetes mellitus. Nutr Metab (Lond). 2011 Aug 16;8:58. doi: 10.1186/1743-7075-8-58.
Results Reference
derived

Learn more about this trial

Effects of Novel Fiber on Glucose Metabolism and Insulin Sensitivity

We'll reach out to this number within 24 hrs